SAVE BIG - BUY BULK - FREE 3 DAY SHIPPING

ABOUT CBD

Cannabidiol (CBD) is the second-most prevalent cannabinoid after THC and the foremost subject of current research. Unlike its cousin tetrahydrocannabinol (THC), CBD doesn’t cause any intoxication. Instead, CBD works in synergy with our bodies in ways that modern science is just beginning to understand.

Most people don’t know that cannabinoids are already in our bodies. Phytocannabinoids (the cannabinoids in the plant) are simply mimicking endocannabinoids (the cannabinoids that naturally occur in our nervous and immune systems).29

Our cannabinoid neuronal receptors, first discovered in the 1980s, are specifically shaped to work with phytocannabinoids. These receptors, named CB1 and CB2, are spread throughout the body, with CB1 receptors concentrated in the brain and CB2 receptors more prevalent in the immune system.14

Our bodies produce two major endocannabinoids: anandamide and 2-arachidonoylglycerol. These compounds activate the endocannabinoid receptors or, alternately, block the receptors so other molecules can’t access them for a while. Blocking or activating the receptors modulates neurological and immune functions, and their action signals other biological processes that help maintain bodily homeostasis, otherwise known as balance.30

Anandamide, named from “ananda,” the Sanskrit word for bliss, is similar in effect to THC and responsible for exercise induced euphoria.31 It has important functions in brain circuits affecting mood, memory, and cognition;30 2-arachidonoylglycerol is far more abundant in our bodies than anandamide and strongly binds to both CB1 and CB2 receptors.32 While it doesn’t produce the pleasant effects of anandamide, it regulates synaptic functions to that having broad effects on neurotransmitters throughout the body.33

Human Body Endocannabinoid system CB1 and CB2 receptors

 

 CBD AND THE FUTURE OF HEALTH AND WELLNESS

You’ve probably heard the news stories about medical marijuana. Maybe you’re curious. Even though the U.S. Food and Drug Administration doesn’t consider cannabis a medicine, consumers are reporting positive effects1 — and researchers are excited, too.

In 2016 and 2017, the National Institutes of Health spent $24 million researching cannabidiol (CBD).2 University research is piling up, too, and, as more positive patient stories pour in, consumers are adopting CBD at a rapid rate.

But at incredible CBD, we believe you should be more informed about your health care choices. Hopefully, this guide will help you learn more about cannabis medicines and if CBD products or cannabis medicines are right for you.

CBD: The New Superfood

People suffering from inflammation, chronic pain, seizures, mental health conditions, and other disorders are tired of expensive pharmaceutical medicines that, according to the Center for Disease Control,5 could have serious side effects. So, they’re trying CBD instead.

But it’s important to note that the U.S. Food and Drug Administration has not evaluated the medicinal efficacy of herbal supplements— or cannabidiol. Claiming that CBD can treat an illness is unlawful; reporting the findings of leading researchers isn’t. And, the latest research is worth reporting! It shows that CBD may have positive effects for people suffering from seizures, anxiety, arthritis, nausea, inflammation, cancer, and a host of other disorders.

 

  1. CBD Hemp Oil Benefits. Reviews & Testimonials. 2018. http://thehempoilbenefits.com/cbd-oil-reviews-testimonials
  2. National Institutes for Health. Estimates of Funding for Various Research, Condition, and Disease Categories. 2017. https://report.nih.gov/categorical_spending.aspx
  3. Aizpurua-Olaizola, et al. Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes. 2016. https://pubs.acs.org/doi/abs/10.1021/acs.jnatprod.5b00949
  4. Leafly. Cannabis Strain Explorer. 2018. https://www.leafly.com/start-exploring
  5. Centers for Disease Control and Prevention. Understanding Side Effects and Adverse Events.2018. https://www.cdc.gov/vaccinesafety/ensuringsafety/sideeffects/index.html
  6. Mayo Clinic. Herbal supplements: what to know before you buy. 2018. https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/herbal-supplements/art-20046714
  7. Solinas, et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. 2012. https://www.ncbi.nlm.nih.gov/pubmed/22624859
  8. Ligresti, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. 2006. https://www.ncbi.nlm.nih.gov/pubmed/16728591
  9. Massi, et al. Cannabidiol as potential anticancer drug. 2013. https://www.ncbi.nlm.nih.gov/pubmed/22506672
  10. Porter; Jacobson. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. 2013. https://www.ncbi.nlm.nih.gov/pubmed/24237632
  11. Tzadok, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. 2016. https://www.ncbi.nlm.nih.gov/pubmed/26800377
  12. Carlini, Cunha. Hypnotic and antiepileptic effects of cannabidiol. 1981. https://www.ncbi.nlm.nih.gov/pubmed/7028792
  13. Sulak. 6 Common Myths and Controversies About High-CBD Cannabis. 2018. https://www.leafly.com/news/cannabis-101/separating-cbd-facts-from-myths
  14. Pertwee. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. 2008. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219532/
  15. Schier, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. 2012. https://www.ncbi.nlm.nih.gov/pubmed/22729452
  16. Crippa, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. 2011. https://www.ncbi.nlm.nih.gov/pubmed/20829306
  17. Leweke, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316151/
  18. Costa, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. 2007. https://www.ncbi.nlm.nih.gov/pubmed/17157290
  19. Malfait, et al. The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine Collagen-Induced Arthritis. 2000. https://www.ncbi.nlm.nih.gov/pubmed/10920191
  20. Hammell, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. 2016. https://www.ncbi.nlm.nih.gov/pubmed/26517407
  21. Liou. Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation. 2010. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083879/
  22. Hampson, et al. Cannabidiol and ()Δ9-tetrahydrocannabinol are neuroprotective antioxidants. 1998. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC20965/
  23. Xiong, et al. Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. 2011. https://www.ncbi.nlm.nih.gov/pubmed/21460829
  24. Guzmán, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. 2006. https://www.ncbi.nlm.nih.gov/pubmed/16804518
  25. Preet, et al. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. 2008. https://www.ncbi.nlm.nih.gov/pubmed/17621270
  26. Caffarel, et al. Cannabinoids: a new hope for breast cancer therapy? 2012. https://www.ncbi.nlm.nih.gov/pubmed/22776349
  27. National Cancer Institute. Cannabis and Cannabinoids (PDQ®)–Health Professional Version. 2018. https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq#section/_11
  28. Rahn. What Are the Side Effects of High-THC Cannabis? 2016. https://www.leafly.com/news/cannabis-101/what-are-the-side-effects-of-high-thc-cannabis
  29. Cresco Labs. What is the endocannabinoid system? 2018. https://www.crescolabs.com/endocannabinoid-system/
  30. Joy, et al. Marijuana and Medicine: Assessing the Science Base. 1999. https://medicalmarijuana.procon.org/sourcefiles/IOM_Report.pdf
  31. Fuss, et al. A runner’s high depends on cannabinoid receptors in mice. 2015. https://www.ncbi.nlm.nih.gov/pubmed/26438875
  32. Sugiura, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. 1995. https://www.ncbi.nlm.nih.gov/pubmed/7575630
  33. Kano, et al. Retrograde signaling at central synapses via endogenous cannabinoids. 2002. https://www.nature.com/articles/4000999
  34. Penn Medicine. Penn Study Shows Nearly 70 Percent of Cannabidiol Extracts Sold Online Are Mislabeled. 2017. https://www.pennmedicine.org/news/news-releases/2017/november/penn-study-shows-nearly-70-percent-of-cannabidiol-extracts-sold-online-are-mislabeled
  35. Steep Hill. Steep Hill Launches New High Detection Cannabis Pesticide Testing in California. 2016. https://www.prnewswire.com/news-releases/steep-hill-launches-new-high-detection-cannabis-pesticide-testing-in-california-300347811.html

SEE ALSO:

http://patientsoutoftime.org/

https://www.projectcbd.org/